Cancer therapeutic targeting using mutant–p53-specific siRNAs

Ifeoma Ubby, Christian Krueger, Roberto Rosato, Wei Qian, Jenny Chang, Kanaga Sabapathy

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Mutations in Tp53 compromise therapeutic response, due either to the dominant-negative effect over the functional wild-type allele; or as a result of the survival advantage conferred by mutant p53 to which cancer cells become addicted. Thus, targeting mutant p53 represents an effective therapeutic strategy to treat over half of all cancers. We have therefore generated a series of small-interfering-RNAs, capable of targeting four p53 hot-spot mutants which represent ~20% of all p53 mutations. These mutant–p53-specific siRNAs (MupSi) are highly specific in silencing the expression of the intended mutants without affecting wild-type p53. Functionally, these MupSis induce cell death by abrogating both the addiction to mutant p53 and the dominant-negative effect; and retard tumor growth in xenografts when administered in a therapeutic setting. These data together demonstrate the possibility of targeting mutant p53 specifically to improve clinical outcome.

Original languageEnglish (US)
Pages (from-to)3415-3427
Number of pages13
JournalOncogene
Volume38
Issue number18
DOIs
StatePublished - May 2 2019

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Cancer therapeutic targeting using mutant–p53-specific siRNAs'. Together they form a unique fingerprint.

Cite this